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CORRECTION Open Access
Correction to: Oral esketamine for
treatment-resistant depression: rationale
and design of a randomized controlled trial
Sanne Y. Smith-Apeldoorn1*, Jolien K. E. Veraart1,2, Jeanine Kamphuis1, Antoinette D. I. van Asselt3, Daan J. Touw4,
Marije aan het Rot5 and Robert A. Schoevers1
Correction to: BMC Psychiatry (2019) 19:375
https://doi.org/10.1186/s12888-019-2359-1
After publication of our article [1] we were notified
that Fig. 1 was wrongly presented.
The correct figure and corresponding title is presented
below:
The original article has been corrected.
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Fig. 1 Trial flowchart. Schematic overview of the study design. T:
Number illustrates number of weeks after baseline
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